GSK

GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides

Retrieved on: 
Wednesday, February 14, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Therapy, Safety, GSK plc, RNA, Drug discovery, Toxicity, GSK, Pharmaceutical industry

Elsie Biotechnologies, Inc. announced today that GSK plc (LSE/NYSE: GSK) has exercised its option to a non-exclusive license to Elsie’s discovery platform, following a successful outcome of the research collaboration , announced in July 2023, to explore the platform capabilities.

Key Points: 
  • Elsie Biotechnologies, Inc. announced today that GSK plc (LSE/NYSE: GSK) has exercised its option to a non-exclusive license to Elsie’s discovery platform, following a successful outcome of the research collaboration , announced in July 2023, to explore the platform capabilities.
  • The option allows GSK to employ Elsie’s discovery platform and P(V) chemistry technologies in its own oligonucleotide drug discovery research.
  • Kevin Green, Chief Operating Officer, Elsie Biotechnologies, said, "We are pleased that GSK has elected to license our platform technology following the research collaboration.
  • Under the terms of the agreement, Elsie will receive a license payment from GSK and could receive additional development and commercial milestones on a target-by-target basis.

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Retrieved on: 
Wednesday, February 14, 2024
Head, SAN, Senior, PD, Merck, Alzheimer's disease, Ionis Pharmaceuticals, GSK, MD, Cell potency, Pharmaceutical medicine, Neurological disorder, Assembly, Aspen, Howard University, Parkinson's disease, IPSC, Therapy, Pharmacology, Internal medicine, Organization, Patient, Pharmaceutical industry

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Key Points: 
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
  • "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer.
  • "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development.
  • Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024
New Drug Application, GSK, Cancer Research UK, JPY, DSM-IV codes, IPK, Trial of the century, EP4, GPR35, GPR52, Genentech, Neurocrine Biosciences, Deficit spending, Therapy, IBD, G&A, Glutamate (neurotransmitter), Partnership, Pfizer, Cerebral vasospasm, Senior, GPCR, NAM, Acquisition, FDA, Inflammatory Bowel Diseases, Schizophrenia, Patient, Tokyo Stock Exchange, Medicine, IPJ, Insomnia, Movement, Pharmaceutical industry

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Global AI Arms Race Accelerates with Cutting-Edge Tech and Strategic Investments

Retrieved on: 
Monday, February 12, 2024
Cloud, Cortex, Computer, Google Cloud, OTCQB, Social media, BX, Avant, Apple silicon, GSK, Roche, Traction, McKinsey & Company, SVP, Investment, Nucor, News, Biophysical environment, Culture, Snowflake Inc., Growth, AAPL, Silicon, ArrayFire, MLX, ESG, FBBank, Consolidated Edison, Computer World, Blackstone Inc., Digital Realty, Memory, Aircraft, Electricity, CNBC, SNOW, Machine learning, Apple Inc., PyTorch, Snowflake, Water, AWS, Environment

VANCOUVER, BC, Feb. 12, 2024 /PRNewswire/ -- USA News Group  - The world is undergoing a massive AI revolution, that according to analysts at McKinsey Global Institute could add the equivalent of up to $4.4 trillion annually in value in the near future. With such immense potential on the line, an AI arms race is underway, several firms are establishing their positions by developing and acquiring new tech, including Avant Technologies Inc. (OTCQB:AVAI), C3.ai, Inc. (NYSE:AI), Snowflake Inc. (NYSE:SNOW), Apple Inc. (NASDAQ:AAPL), and even asset management firm Blackstone Inc. (NYSE:BX).

Key Points: 
  • Along the important road towards this new technological integration, businesses trying to use AI in their products are facing big challenges.
  • These challenges are mostly because of the high costs of computing power and a global shortage of data storage expected by 2025.
  • Avant is dedicated to advancing AI technology and is creating a specialized computing environment specifically designed for AI applications.
  • "In this new AI era, generative AI and large language models will reshape how we live, work and do business."

Global AI Arms Race Accelerates with Cutting-Edge Tech and Strategic Investments

Retrieved on: 
Monday, February 12, 2024
Cloud, Cortex, Computer, Google Cloud, OTCQB, Social media, BX, Avant, Apple silicon, GSK, Roche, Traction, McKinsey & Company, SVP, Investment, Nucor, News, Biophysical environment, Culture, Snowflake Inc., Growth, AAPL, Silicon, ArrayFire, MLX, ESG, FBBank, Consolidated Edison, Computer World, Blackstone Inc., Digital Realty, Memory, Aircraft, Electricity, CNBC, SNOW, Machine learning, Apple Inc., PyTorch, Snowflake, Water, AWS, Environment

VANCOUVER, BC, Feb. 12, 2024 /PRNewswire/ -- USA News Group  - The world is undergoing a massive AI revolution, that according to analysts at McKinsey Global Institute could add the equivalent of up to $4.4 trillion annually in value in the near future. With such immense potential on the line, an AI arms race is underway, several firms are establishing their positions by developing and acquiring new tech, including Avant Technologies Inc. (OTCQB:AVAI), C3.ai, Inc. (NYSE:AI), Snowflake Inc. (NYSE:SNOW), Apple Inc. (NASDAQ:AAPL), and even asset management firm Blackstone Inc. (NYSE:BX).

Key Points: 
  • Along the important road towards this new technological integration, businesses trying to use AI in their products are facing big challenges.
  • These challenges are mostly because of the high costs of computing power and a global shortage of data storage expected by 2025.
  • Avant is dedicated to advancing AI technology and is creating a specialized computing environment specifically designed for AI applications.
  • "In this new AI era, generative AI and large language models will reshape how we live, work and do business."

Saudi Sports for All Federation Welcomes More Than 20,000 Participants for 2024 Riyadh Marathon

Retrieved on: 
Sunday, February 11, 2024
Women, Sports, Consumer, Men, Running, CALO, Woman, Ministry, Multimedia, GSK, Riyadh Marathon, SAB, Hisamitsu, Female, Sport, SFA, Male, PepsiCo, JPMorgan Chase, Interior design

View the full release here: https://www.businesswire.com/news/home/20240211783273/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240211783273/en/
    Riyadh Marathon Presented by SAB (Graphic: AETOSWire)
    For the first time, the start and finish line, and the accompanying Marathon Village, were located next to Kingdom Arena and Boulevard World.
  • From there, competitors of all ages and abilities could enjoy one of four races – the full marathon (42.2km), half marathon (21.1km), 10km, and 4km family run.
  • Across the four races, there were more than 20,000 participants, with a significant increase in female runners, exceeding 7,200.
  • The event was also sponsored by JPMorgan, Hisamitsu, Activia, L’Oréal, GSK, CALO, Kudu, Delta Sports, and MDLBeast.

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

Retrieved on: 
Thursday, February 8, 2024
Partnership, Alector, GSK plc, SAN, Deficit spending, Patient, Safety, Cerebrospinal fluid, CSF, Brain, Risk, Plasma, Arnon Rosenthal, ALEC, GSK, Frontotemporal dementia, PD, Pharmaceutical industry

Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • We look forward to continuing the development of AL101 in this Phase 2 trial with our partner GSK who is operationalizing the trial.
  • The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB).
  • The study results demonstrated that the PK and PD profile supported the progression to Phase 2 clinical trials for more prevalent neurodegenerative conditions, such as AD and Parkinson’s disease.

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, February 7, 2024
GSK plc, PGS, Pharmacokinetics, SAN, Growth, Net, Inflammation, Table, Investigational New Drug, Research, SITC, Genetics, NK, Society, Consumer, Patient, IND, African Americans, FDA, Database, Immunotherapy, Therapy, Total, Premium, Webcast, Cancer, 23andMe, GSK, Workforce, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.
  • “The Company had a very productive third quarter, with meaningful strategic progress across all three business lines,” said Anne Wojcicki, Co-Founder & CEO of 23andMe.
  • Full year Adjusted EBITDA deficit is adjusted to be in the range of $185 to $180 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, February 7, 2024, to discuss the financial results for Q3 FY2024 and report on business progress.

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Alector, GSK plc, SAN, FDA, Neurodegenerative disease, Food, Arnon Rosenthal, ALEC, GSK, Frontotemporal dementia, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN).
  • “In partnership with GSK, we are encouraged and excited by this FDA Breakthrough Designation.
  • FTD-GRN is a rare and rapidly progressing neurodegenerative disease and one of the most common causes of early onset dementia," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
  • Latozinemab, the most advanced progranulin-elevating candidate in clinical development for FTD-GRN, is currently being studied in the pivotal INFRONT-3 Phase 3 study, which achieved target enrollment in October 2023.”
    The FDA granted latozinemab Breakthrough Therapy Designation for FTD-GRN based upon data from the INVOKE-2 Phase 2 clinical trial of latozinemab in FTD-GRN participants.

Experienced Life Sciences Leader Joins IPS as Regional Director to Lead New Australian Office

Retrieved on: 
Tuesday, February 6, 2024
Consulting, Biotechnology, Manufacturing, Construction & Property, Professional Services, Other Health, Health, Pharmaceutical, Architecture, Engineering, Other Construction & Property, Growth, IPS, ANZ, Cell, Research, Sanofi, Patient, AstraZeneca, Gene, GSK

IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.

Key Points: 
  • IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.
  • Before joining IPS, Gordon served in leadership roles across the APAC region from Singapore to Shanghai and Melbourne.
  • “Gordon’s appointment as Regional Director, ANZ allows us to further support our clients in bringing life-changing therapies to patients in Australia and beyond,” said Matthew Shippey, Managing Director, APAC.
  • Gordon’s leadership will be instrumental in fostering growth within the Australian market, positioning the company as a leading force in the life sciences and pharmaceutical manufacturing sectors.